Avian Mycoplasmosis in Poultry: Pathogenesis, Diagnostic Approaches, and Control Strategies

Abstract

Avian mycoplasmosis, caused primarily by Mycoplasma gallisepticum (MG) and Mycoplasma synoviae (MS), represents a significant economic burden to the global poultry industry through chronic respiratory disease, infectious synovitis, and reduced production parameters. This review synthesizes current understanding of mycoplasmal pathogenesis mechanisms including cytadherence, immune evasion, and inflammatory cascades. Diagnostic methodologies are evaluated ranging from conventional serology to advanced molecular techniques including multiplex real-time polymerase chain reaction (PCR), loop-mediated isothermal amplification (LAMP), and high-throughput sequencing for molecular epidemiology. Control strategies encompass biosecurity protocols, vaccination approaches utilizing live attenuated and recombinant vector vaccines, and antimicrobial stewardship guided by pharmacokinetic/pharmacodynamic principles. Emerging research on host-pathogen coevolution, polymicrobial interactions, and novel therapeutic targets including ion channel modulation and nuclease inhibition are discussed.

Introduction

Mycoplasma gallisepticum and Mycoplasma synoviae are wall-less bacteria belonging to the class Mollicutes, characterized by reduced genomes (0.58–1.38 Mb) and dependence on host-derived nutrients including cholesterol, nucleotides, and amino acids [1]. These pathogens exhibit strict host specificity for avian species, primarily chickens (Gallus gallus domesticus) and turkeys (Meleagris gallopavo), though natural infections occur in diverse avian taxa including wild turkeys, parrots, and macaws [2, 3]. Transmission occurs via horizontal respiratory routes, vertical transmission through infected eggs, and fomite-mediated spread. Economic losses manifest as decreased feed conversion efficiency, reduced egg production and quality, increased condemnation rates at processing, and costs associated with medication and vaccination programs.

The clinical presentation differs between the two species. MG infection typically produces chronic respiratory disease (CRD) characterized by tracheal rales, nasal discharge, conjunctivitis, and airsacculitis, particularly when exacerbated by environmental stressors or concurrent viral infections such as avian influenza virus (AIV) or infectious bronchitis virus (IBV) [4]. MS infection manifests primarily as infectious synovitis with joint swelling and lameness, though respiratory and subclinical presentations are common. Both pathogens predispose hosts to secondary bacterial infections, notably Escherichia coli, leading to colibacillosis and airsacculitis complexes [1].

Pathogenesis Mechanisms

Cytadherence and Colonization

The initial step in mycoplasmal pathogenesis involves attachment to host respiratory or synovial epithelium mediated by specialized tip organelles and surface adhesins. In MG, the cytadherence complex comprises GapA, CrmA, and associated accessory proteins that bind sialylated oligosaccharides on host ciliated epithelial cells [5]. This attachment triggers cytoskeletal rearrangements in host cells, facilitating intimate contact and preventing mucociliary clearance. MS expresses distinct adhesins including VlhA (variable lipoprotein hemagglutinin) proteins that undergo phase variation through site-specific DNA inversions, enabling immune evasion and tissue tropism modulation [6].

Immune Evasion Strategies

Both species employ sophisticated immune evasion mechanisms. Antigenic variation of surface lipoproteins through combinatorial gene conversion and point mutations allows escape from humoral immunity [6]. The absence of a cell wall eliminates peptidoglycan-mediated pathogen-associated molecular pattern (PAMP) recognition by Toll-like receptor 2 (TLR2), though lipoproteins remain potent TLR2 agonists. Mycoplasmas secrete nucleases (e.g., TatD DNase) that degrade neutrophil extracellular traps (NETs), impairing innate immune containment [7]. Additionally, mycoplasmal membrane components modulate host cytokine profiles, often suppressing protective Th1 responses while promoting Th2/Th17 polarization associated with chronic inflammation [8, 7].

Inflammatory Cascades and Tissue Damage

Following colonization, mycoplasmas induce pro-inflammatory cytokine production including interleukin-1β (IL-1β), IL-6, tumor necrosis factor-α (TNF-α), and chemokines (CXCL8, CCL20) via TLR2/MyD88/NF-κB signaling [8, 7]. The MAPK pathway (ERK, JNK, p38) is activated, driving expression of matrix metalloproteinases (MMPs) that degrade extracellular matrix components in tracheal mucosa and synovial membranes [7]. Recent evidence demonstrates that Scutellaria baicalensis-derived extracellular vesicles attenuate MG-induced inflammation by inhibiting TRPC1-STIM1/ORAI1 calcium channel signaling, reducing NF-κB nuclear translocation and downstream cytokine production [8]. Similarly, luteolin targets TatD nuclease and the MAPK pathway, offering a multifaceted approach against MG infection [7].

Polymicrobial Interactions

Field conditions frequently involve polymicrobial infections that exacerbate disease severity. Co-infection with Cryptosporidium baileyi enhances MS colonization and aggravates tissue damage in chickens through mechanisms involving disrupted epithelial barrier integrity and altered immune microenvironment [9]. Concurrent AIV infection creates synergistic respiratory pathology, as demonstrated in a broiler farm case study where H9N2 AIV and MS co-infection resulted in severe airsacculitis and mortality [4]. Cross-sectional studies in free-range layers reveal complex pathogen interactions among MG, MS, IBV, avian metapneumovirus (aMPV), and Ornithobacterium rhinotracheale (ORT), with statistical associations indicating facilitation of mycoplasmal persistence by viral co-infections [1]. Long-term coevolutionary history between host populations and pathogens predicts higher behavioral tolerance of infection, suggesting host genetic background influences disease outcomes [5].

Diagnostic Approaches

Serological Methods

Serology remains the cornerstone of flock-level surveillance and trade certification. The serum plate agglutination (SPA) test detects IgM antibodies within 7–10 days post-infection but lacks specificity due to cross-reactivity with other mycoplasmas and non-specific agglutinins. Enzyme-linked immunosorbent assay (ELISA) kits targeting species-specific antigens (e.g., MG pMGA, MS VlhA) offer higher throughput and quantitative results suitable for monitoring vaccine responses and field exposure [3]. Hemagglutination inhibition (HI) testing provides strain-specific resolution but requires live antigen preparation and is labor-intensive. Serological evidence in trafficked parrots and macaws in Colombia demonstrated MG and MS exposure, highlighting the role of wildlife trade in pathogen dissemination [3].

Molecular Diagnostics

Conventional and Real-Time PCR

Polymerase chain reaction targeting the 16S rRNA gene, mgc2 (MG), or vlhA (MS) provides sensitive detection directly from swabs, tissues, or environmental samples. A multiplex TaqMan real-time PCR assay enables differential identification of wild-type and vaccine strains of MG (F-strain, 6/85, ts-11) by targeting strain-specific genomic regions, critical for distinguishing vaccine reversion from field challenge [10]. Quantitative PCR (qPCR) allows bacterial load quantification, correlating with disease severity and transmission risk.

Loop-Mediated Isothermal Amplification (LAMP)

LAMP assays offer rapid, field-deployable detection with minimal equipment requirements. A high-throughput colorimetric LAMP assay for MG incorporates intelligent algorithm-assisted analysis for automated result interpretation, achieving detection limits of 10 copies per reaction within 30 minutes [11]. A field-ready colorimetric LAMP assay utilizing rapid DNA extraction (boiling or commercial-free methods) enables on-site testing with visual color change readout, suitable for resource-limited settings [12]. These assays target conserved genomic regions (e.g., mgc2, 16S rRNA) with primer sets comprising six primers recognizing eight distinct sequences, ensuring high specificity.

Sequencing and Molecular Epidemiology

High-throughput sequencing facilitates whole-genome analysis for outbreak tracing, antimicrobial resistance (AMR) surveillance, and vaccine strain differentiation. A 14-year molecular typing study of MS in industrial and backyard poultry in Italy employed multilocus sequence typing (MLST) and vlhA sequencing, revealing distinct population structures between production systems and evidence of inter-farm transmission [6]. Phylogenomic analysis identifies recombination hotspots and tracks the spread of resistance-conferring mutations in 23S rRNA (macrolide/lincosamide resistance) and parC/gyrA (fluoroquinolone resistance).

Diagnostic Algorithm

flowchart TD
    A[Clinical Suspicion / Routine Surveillance], > B{Sample Type}
    B, >|Serum| C[ELISA Screening]
    B, >|Swab / Tissue / Lavage| D[Molecular Testing]
    C, >|Positive| E[Confirmatory HI / Western Blot]
    C, >|Negative| F[Repeat in 2-3 Weeks if High Risk]
    D, > G{Test Platform}
    G, >|Laboratory| H[Multiplex qPCR<br/>Wild-type vs Vaccine Differentiation]
    G, >|Field / Point-of-Care| I[Colorimetric LAMP<br/>Rapid DNA Extraction]
    H, >|Positive| J[Quantification / Sequencing]
    I, >|Positive| J
    J, > K[Molecular Typing: MLST / vlhA / WGS]
    K, > L[Epidemiological Linkage / Source Tracing]
    L, > M[Control Strategy Adjustment]
    E, > M
    F, > M

Comparative Diagnostic Performance

Control Strategies

Biosecurity Measures

Effective biosecurity constitutes the primary barrier against mycoplasmal introduction and spread. Key components include:

1. Traffic control: Restricted access zones, dedicated personnel and equipment per house, vehicle disinfection stations.
2. Rodent and wild bird exclusion: Sealed housing, screened ventilation, feed spill management to reduce mechanical vectors.
3. Sanitation: Terminal disinfection with validated agents (oxidizing agents, quaternary ammonium compounds) effective against mycoplasmas; downtime between flocks (≥14 days).
4. Monitoring: Routine serological surveillance (monthly ELISA), environmental sampling (dust, water, equipment swabs) via qPCR/LAMP, sentinel bird placement.
5. Source verification: Procurement from MG/MS-free breeder flocks certified under National Poultry Improvement Plan (NPIP) or equivalent programs.

Wildlife reservoirs, particularly free-ranging wild turkeys, maintain mycoplasmal populations capable of spillover to commercial operations [2]. Regional surveillance of wild populations informs risk assessment for nearby poultry facilities.

Vaccination Programs

Live Attenuated Vaccines

Traditional live vaccines include MG F-strain, 6/85, and ts-11, and MS-H and MS-1 strains. These vaccines colonize the upper respiratory tract, inducing local mucosal immunity (IgA), cell-mediated immunity (CD4+ and CD8+ T cells), and systemic antibody responses. Evaluation of vaccination programs in layer pullets using recombinant fowlpox-MG vaccine demonstrated comparable protection to F-strain live vaccines with reduced post-vaccination reactions and no vertical transmission risk [13]. However, live vaccines retain potential for bird-to-bird spread, reversion to virulence, and interference with serological monitoring.

Recombinant Vector Vaccines

Recombinant fowlpox virus (FPV) and fowl adenovirus serotype 4 (FAdV-4) vectors expressing mycoplasmal protective antigens (e.g., MG GapA, MS VlhA, P50) offer safety advantages. Vaccination with recombinant FAdV-4-P50 conferred protection against MS challenge, reducing colonization and synovitis lesions [14]. These vectors enable differentiation of infected from vaccinated animals (DIVA) strategies when combined with companion diagnostic assays targeting non-vector antigens.

Vaccine Efficacy Considerations

Vaccine efficacy is influenced by maternal antibody interference, route of administration (eye-drop, spray, drinking water, in ovo), dose titration, and challenge strain heterogeneity. Prime-boost regimens combining live priming with vectored boosting optimize breadth and duration of immunity. Vaccination does not prevent colonization but reduces clinical severity, shedding duration, and horizontal transmission.

Antimicrobial Therapy and Stewardship

Antimicrobial treatment mitigates clinical signs and reduces shedding but does not eliminate infection. Macrolides (tylosin, tilmicosin), tetracyclines (doxycycline, chlortetracycline), fluoroquinolones (enrofloxacin), and pleuromutilins (tiamulin, valnemulin) are commonly used. A novel pleuromutilin derivative (APTM) demonstrated favorable pharmacokinetic/pharmacodynamic (PK/PD) relationships against MG, with high tissue penetration in respiratory tract and prolonged post-antibiotic effect [15]. PK/PD indices (AUC/MIC, Cmax/MIC, time above MIC) guide dosing regimen optimization to maximize efficacy and minimize resistance selection.

Antimicrobial resistance surveillance reveals increasing macrolide-lincosamide-streptogramin B (MLSB) resistance mediated by 23S rRNA mutations and fluoroquinolone resistance via parC/gyrA mutations. Rotation policies, combination therapy, and adherence to withdrawal periods are essential stewardship practices. Alternative therapeutic approaches targeting host pathways (TRPC1-STIM1/ORAI1 inhibition, MAPK modulation) or bacterial virulence factors (TatD nuclease inhibition) represent promising adjunctive strategies [8, 7].

Emerging Research Directions

Host-Pathogen Coevolution

Longitudinal studies indicate that host populations with longer histories of pathogen exposure exhibit higher behavioral tolerance, manifested as reduced sickness behaviors (anorexia, lethargy) during infection [5]. This tolerance mechanism, distinct from resistance (pathogen load reduction), involves neuroimmune modulation and may be leveraged in breeding programs for resilient poultry lines.

Microbiome Modulation

The respiratory and gut microbiomes influence mycoplasmal colonization resistance. Dysbiosis induced by antibiotics, stress, or viral infections creates niches for mycoplasmal expansion. Probiotic and prebiotic interventions targeting Lactobacillus and Bifidobacterium species show potential for competitive exclusion and immunomodulation, though controlled field trials are needed.

Computational Approaches

Bioinformatics pipelines integrating WGS data, metadata, and geospatial information enable real-time phylogenetic tracking and transmission network reconstruction. Machine learning models trained on genomic features predict virulence potential, host range, and antimicrobial resistance phenotypes. These tools support precision epidemiology and targeted intervention strategies.

Conclusion

Avian mycoplasmosis remains a complex, multifactorial disease requiring integrated management approaches. Advances in molecular diagnostics, particularly multiplex qPCR and field-deployable LAMP, enable rapid, strain-specific detection critical for outbreak response. Vaccination strategies continue to evolve toward safer, DIVA-compatible platforms. Antimicrobial stewardship guided by PK/PD principles preserves therapeutic efficacy. Understanding polymicrobial interactions, host-pathogen coevolution, and novel virulence mechanisms informs next-generation control measures. Sustained surveillance in commercial, backyard, and wildlife populations, coupled with coordinated international data sharing, is essential for mitigating the global impact of Mycoplasma gallisepticum and Mycoplasma synoviae.

References

[1] Rodrigo CH, Kulappu Arachchige SN, Bushell RN et al. Complex pathogen interactions in upper respiratory tract infections in commercial free-range layers: A cross-sectional study. Vet Microbiol. 2026. https://pubmed.ncbi.nlm.nih.gov/42190304/

[2] Edge AC, Moorman CE, Pacifici K et al. Regional Pathogen Surveillance of Free-Ranging Wild Turkeys (Meleagris gallopavo) in North Carolina, USA. J Wildl Dis. 2026. https://pubmed.ncbi.nlm.nih.gov/41667058/

[3] Marín-Villa J, Alzate-Vargas JF, Ramírez TG et al. Serological evidence and risk factors of Mycoplasma gallisepticum and Mycoplasma synoviae exposure in trafficked parrots and macaws in Colombia. Open Vet J. 2025. https://pubmed.ncbi.nlm.nih.gov/41630737/

[4] Hartady T, Sugandi SD, Viqih M. A Case of Avian Influenza Co-Infection and Multifactorial Diseases in a Broiler Chicken Farm in Majalengka, West Java, Indonesia. Vet Sci. 2026. https://pubmed.ncbi.nlm.nih.gov/42076736/

[5] Adelman JS, Henschen AE, Tillman FE Jr et al. The devil you know: a longer history of pathogen coevolution predicts higher behavioural tolerance of infection among host populations. Biol Lett. 2026. https://pubmed.ncbi.nlm.nih.gov/42124517/

[6] Stefani E, Morales-Arce AY, Nai G et al. Molecular typing of Mycoplasma synoviae in industrial and backyard poultry: a 14-year study in Italy. Appl Environ Microbiol. 2026. https://pubmed.ncbi.nlm.nih.gov/41817199/

[7] Liu W, Wang S, Hu J et al. Targeting TatD nuclease and the MAPK Pathway: Luteolin multifaceted approach against Mycoplasma gallisepticum infection. Poult Sci. 2026. https://pubmed.ncbi.nlm.nih.gov/41548475/

[8] Xu F, Bao L, Yao Y et al. Mechanism of Scutellaria baicalensis extracellular vesicles in attenuating Mycoplasma gallisepticum-induced inflammation via TRPC1 - STIM1/ORAI1 channel inhibition. Poult Sci. 2026. https://pubmed.ncbi.nlm.nih.gov/41905072/

[9] Zhang Y, Li Y, Wang Z et al. Cryptosporidium baileyi and Mycoplasma synoviae co-infection enhances M. synoviae colonization and aggravates tissue damage in chickens. Front Microbiol. 2026. https://pubmed.ncbi.nlm.nih.gov/42158394/

[10] Xin J, Zhang J, Liang S et al. A multiplex TaqMan real-time PCR assay for differential identification of wild-type and vaccine strains of Mycoplasma gallisepticum. Poult Sci. 2026. https://pubmed.ncbi.nlm.nih.gov/41702344/

[11] Jing W, Cai Q, Liang Y et al. High-throughput colorimetric LAMP detection of Mycoplasma gallisepticum with intelligent algorithm-assisted analysis. Anal Methods. 2026. https://pubmed.ncbi.nlm.nih.gov/41891257/

[12] Mayne R, Pant SD, Huang J et al. A field-ready colourimetric LAMP assay for detection of Mycoplasma gallisepticum using rapid DNA extraction. Res Vet Sci. 2026. https://pubmed.ncbi.nlm.nih.gov/41785617/

[13] Hashish A, Chaves M, Osemeke O et al. Evaluation of Vaccination Programs in Layer Pullets Using Recombinant Fowl-Pox Mycoplasma gallisepticum Vaccine in Comparison to Commercially Available F-Strain Live Vaccines. Avian Dis. 2026. https://pubmed.ncbi.nlm.nih.gov/41973009/

[14] Liu Y, Li W, Li G et al. Protection of chickens against M. synoviae infection by vaccination with a recombinant fowl adenovirus 4-P50. Microb Pathog. 2026. https://pubmed.ncbi.nlm.nih.gov/41887300/

[15] Yang W, Ding H, Ma X et al. Pharmacokinetic/pharmacodynamic relationship of a novel pleuromutilin derivative APTM against Mycoplasma gallisepticum. Poult Sci. 2026. https://pubmed.ncbi.nlm.nih.gov/41650639/